Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568744 | 0.93 | CFTR (0.60) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL13814561 | 0.93 | CFTR (0.60) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL21929291 | 0.86 | CFTR (0.56) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL3872035 | 0.85 | CFTR (0.50) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL195591 | 0.85 | KDM4E (0.61) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL28922445 | 0.84 | CFTR (0.66) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL11922634 | 0.84 | CFTR (0.49) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL12685916 | 0.82 | ALDH1A1 (0.49) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL15543856 | 0.81 | CFTR (0.46) | CFTRKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL12303359 | 0.81 | KDM4E (0.56) | CFTRKDM4EALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115577-A1 | BCL-2 Inhibitors | Eil Therapeutics, Inc. | 2025-04-10 | — | — | US | disclosed |
| EP-4457223-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-114716478-A | 6-substituted phosphoryl quinazoline derivative and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-106146412-A | Quinazoline derivant and its preparation method and application | 广州市恒诺康医药科技有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115577-A1 | BCL-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | CFTR 549/4885KDM4E 3326/4885ALDH1A1 1753/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CFTR 216/4885KDM4E 3069/4885ALDH1A1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.